10x Genomics, Inc. (TXG) fair value analysis
Nasdaq · Updated 2026-09-07
10x Genomics, Inc. is a life sciences company that develops and sells instruments and consumables for analyzing genes and proteins at the single-cell level, enabling researchers to study biological systems with greater precision. The company operates globally, serving research institutions, hospitals, and pharmaceutical companies across multiple continents.
Valuation status
Awaiting full valuationTXG does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $47.01
- Sector
- Healthcare
- 12-month range
- $12.39–$47.01
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for TXG
- Our model validated 2 trailing price-to-earnings windows for TXG, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $12.39–$47.01.
- The 14-day relative strength index sits at a neutral 65.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TXG
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent TXG news
TickrTrends' derived news-sentiment signal for TXG is currently leaning positive, computed from recent coverage.
- 10x Genomics Inc (TXG) Shares Fall 5.1% -- GF Value Says Still Overvalued (gurufocus.com, 2026-08-29)
TickrTrends take: TXG shares declined recently, and the company remains classified as overvalued according to GF Value metrics, which aligns with TickrTrends' current stance of awaiting full valuation assessment. For investors focused on valuation dynamics, the ongoing gap between market price and intrinsic value estimates represents a key metric to monitor as the company operates within the competitive Healthcare sector. Movement in this valuation gap could provide important signals about when a more definitive verdict becomes appropriate for the stock. - 10x Genomics Inc (TXG) Director Shehnaaz Suliman Sells 2,207 Shares (gurufocus.com, 2026-08-26)
TickrTrends take: Director Shehnaaz Suliman's sale of 2,207 shares represents an insider transaction that warrants attention from investors evaluating 10x Genomics' fundamental value, particularly given that TickrTrends is currently awaiting full valuation data for the Healthcare sector company. Insider selling activity can provide signals about management's confidence levels and capital allocation priorities, making it relevant context as a complete valuation picture develops. Observers tracking TXG should note whether this transaction is part of a broader pattern of insider moves or represents an isolated event as additional valuation metrics become available.
What people are saying
Follow the TXG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TXG stock undervalued?
TXG does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TXG's TickrTrends verdict?
TXG is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is TXG overbought or oversold?
TXG's 14-day RSI is in neutral territory - neither overbought nor oversold.